Breast SACT regimens
Whilst every effort is made to ensure the accuracy of the information in a given regimen it cannot be guaranteed that the regimen is fully up to date, because of the dynamic nature of cancer treatment. Check the regimen details for the specific indication the regimen may be used / funded in. See our disclaimer.
Paclitaxel may be administered via a DEHP free line instead of the polyethylene lined giving set specified in the regimens.
Trastuzumab deruxtecan and trastuzumab emtansine should be administered via administration sets with polyethersulfone (PES) ≤0.22micron inline filter (but do not require polyethylene lined giving set).
Breast Neoadjuvant
- Docetaxel Carboplatin Phesgo (neoadjuvant node negative or unknown nodal status)
- Docetaxel Carboplatin Phesgo (neoadjuvant node positive)
- EC Docetaxel
- EC Docetaxel Phesgo (neoadjuvant node negative or unknown nodal status)
- EC Docetaxel Phesgo (neoadjuvant node positive)
- EC Docetaxel Trastuzumab
- EC Paclitaxel (dose dense)
- EC Paclitaxel Carboplatin
- Paclitaxel albumin-bound (nab-paclitaxel)
- Paclitaxel Carboplatin EC
- Paclitaxel weekly
- Paclitaxel weekly Phesgo (following 3-4 cycles EC only)
- Pembrolizumab Paclitaxel Carboplatin EC
- Pembrolizumab Paclitaxel Carboplatin weekly EC
- Pertuzumab Trastuzumab (IV) substitution
Breast Adjuvant
- Abemaciclib with endocrine therapy
- Capecitabine
- Docetaxel Carboplatin Phesgo (adjuvant)
- Docetaxel Carboplatin Trastuzumab
- Docetaxel Cyclophosphamide
- EC
- EC Docetaxel
- EC Docetaxel Phesgo (adjuvant)
- EC Docetaxel Trastuzumab
- EC Paclitaxel (dose dense)
- EC Paclitaxel Carboplatin
- Neratinib
- Olaparib
- Paclitaxel albumin-bound (nab-paclitaxel)
- Paclitaxel Carboplatin EC
- Paclitaxel weekly
- Paclitaxel weekly Phesgo (following 3-4 cycles EC only)
- Paclitaxel weekly Trastuzumab
- Pertuzumab Trastuzumab (SC) (Phesgo) (adjuvant)
- Pertuzumab Trastuzumab (IV) substitution
- Ribociclib with aromatase inhibitor
- Trastuzumab emtansine
Breast Metastatic
- Abemaciclib Fulvestrant
- Abemaciclib with aromatase inhibitor
- Alpelisib Fulvestrant
- Atezolizumab Paclitaxel albumin-bound
- Capecitabine
- Capivasertib Fulvestrant
- Carboplatin
- Cyclophosphamide Methotrexate
- Docetaxel
- Docetaxel Phesgo
- EC
- Elacestrant
- Epirubicin weekly
- Eribulin (Blueteq registration no longer required)
- Everolimus with exemestane (Blueteq registration no longer required)
- Fulvestrant (local funding)
- Gemcitabine Carboplatin
- MMM
- Olaparib
- Paclitaxel albumin-bound (nab-paclitaxel)
- Paclitaxel Carboplatin
- Paclitaxel (3 weeks on 1 week off)
- Paclitaxel weekly Trastuzumab
- Palbociclib Fulvestrant
- Palbociclib with aromatase inhibitor
- Pembrolizumab Paclitaxel
- Pembrolizumab Paclitaxel albumin-bound (nab-paclitaxel)
- Pertuzumab Trastuzumab (IV) substitution
- Ribociclib Fulvestrant
- Ribociclib with aromatase inhibitor
- Sacituzumab govitecan
- Talazoparib
- Trastuzumab deruxtecan
- Trastuzumab emtansine
- Trastuzumab monotherapy
- Tucatinib Capecitabine Trastuzumab
- Vinorelbine (oral)
Bisphosphonates
- Bisphosphonates and denosumab (prevention) (TV adopted)
SACT regimens written by S Coutts
For further information please contact us.